RecruitingNCT07046494

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolarity type I

This study is recruiting. It focuses on bipolarity and currently lists participation information in the United States.

BipolarityDrugFrom 18 Years to 65 Years

In plain English

Key information made simple

This study is comparing RAP-219 with placebo for people with Bipolarity type I. Participants receive RAP-219 or placebo and complete study visits and assessments. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a hospital, with sites including Pillar Clinical Research - Little Rock, Woodland International Research Group in Little Rock, and Woodland Research Northwest in Rogers. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis and being able to follow the planned visits or tasks, while common reasons not to take part include active substance or alcohol problems that could affect the results and other factors that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Public study data

Key study information

Official title: A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder
Condition: Bipolar 1 Disorder
Study status: Recruiting
Phase: Phase 2
Sponsor / lead affiliation: Rapport Therapeutics Inc.
Intervention: RAP-219, Placebo
Location / country: United States
Contact: Dawn F Fenton, Leslie Smith, MD, Robert Billingsley, MD, Charmaine Semeniuk, MD, Charmaine Semeniuk, Haig Goenjian, MD, Haig Goenjian, Daniel Chueh, MD, Mohammad Asim Nisar, MD, Patrick Pinchinat, MD, Patrick Pinchinat, Edwin Gomez, MD, Rishi Kakar, MD, Danesh Alam, MD, Kimball Johnson, MD, Roueen Rafeyan, MD, Kulsoom Juniad, MD, Peter Weiden, Peter Weiden, MD, Kurian Abraham, MD, Kurian Abraham, Samuel Collier, MD, Dominick D'Aunno, MD
Email: dfenton@rapportrx.com
Phone: (857) 323-9048
Registry: ClinicalTrials.gov

Why this study may matter

This study may matter because it is evaluating RAP-219, Placebo in a structured research setting. For people exploring bipolarity research, clear information about the goal, status, contacts, and official source can support better questions before any decision.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: NCT07046494. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in United States.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor: Rapport Therapeutics Inc.
Sponsor type: Biotech company
Main activity: medication or study treatment
Intervention: RAP-219, Placebo
Time commitment: long follow-up or multiple visits
Study phase: Phase 2
Enrollment: Not available
Recruitment status: Recruiting
Source: Official registry link

FAQ

Questions about this study

What is Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolarity type I?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Rapport Therapeutics Inc.. Based on the sponsor name or official registry information, it appears to be a biotech company. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve medication or study treatment, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is Phase 2. Earlier-phase studies are often more focused on safety, dose, or feasibility, while later-phase studies usually involve more participants and more information about the intervention. The official source record gives the most accurate details. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.